AI and Machine Learning in HealthTech: Investment Opportunities

June 28, 2024

Artificial Intelligence (AI) and Machine Learning (ML) are no longer just buzzwords—they are transformative technologies reshaping various industries, including healthcare. AI involves the simulation of human intelligence processes by machines, while ML, a subset of AI, refers to systems that can learn from data, identify patterns, and make decisions with minimal human intervention. Together, they hold immense potential to revolutionize health technology by enhancing efficiency, accuracy, and personalization in medical care.

In the realm of health technology, AI and ML are driving significant advancements. These technologies are being integrated into diagnostic tools, enabling faster and more accurate disease detection. They are also playing a crucial role in the development of personalized medicine, tailoring treatments to individual patients based on their unique genetic makeup and health data.

Predictive analytics powered by AI can forecast disease outbreaks and patient outcomes, while AI-driven drug discovery accelerates the process of bringing new treatments to market. Additionally, AI is optimizing administrative workflows in healthcare institutions, reducing costs, and improving operational efficiency.

As AI and ML continue to evolve, the opportunities for investment in health technology are vast and varied. Identifying these opportunities is crucial for investors looking to capitalize on the growth of this dynamic sector. With the healthcare industry increasingly embracing digital transformation, investing in AI and ML technologies can yield significant returns while contributing to the advancement of global health. However, navigating this rapidly evolving field requires a deep understanding of the technologies, market trends, and the specific needs of the healthcare sector.

In this blog, we will explore the current landscape of AI and machine learning in health technology, delve into the major areas where these technologies are making an impact, and discuss key metrics for evaluating investment opportunities. By examining successful case studies and understanding the potential risks and challenges, investors can make informed decisions and tap into the transformative power of AI and ML in HealthTech.

The Current Landscape of AI and Machine Learning in HealthTech

AI and machine learning are already transforming numerous aspects of healthcare, making processes more efficient and outcomes more precise. Here, we provide an overview of the key applications of AI/ML in health technology:

AI and ML are revolutionizing medical diagnostics and imaging by enhancing the accuracy and speed of disease detection. Machine learning algorithms can analyze medical images such as X-rays, CT scans, and MRIs with incredible precision, often identifying abnormalities that might be missed by the human eye. For instance, AI systems have demonstrated remarkable accuracy in detecting cancers, heart conditions, and neurological disorders. Companies like Zebra Medical Vision and Aidoc are at the forefront, developing AI tools that assist radiologists in diagnosing complex conditions more accurately and quickly.

Personalized medicine, also known as precision medicine, leverages AI and ML to tailor medical treatments to individual patients based on their genetic, environmental, and lifestyle factors. This approach is especially promising in oncology, where treatments can be customized to target specific genetic mutations in a patient's tumor. AI algorithms analyze vast amounts of genomic data to identify the most effective treatment plans for patients. Companies like Tempus and Foundation Medicine are pioneers in this field, using AI to develop personalized cancer therapies and improve patient outcomes.

Predictive analytics in healthcare uses AI to analyze historical and real-time data to predict future health events. This application is vital for early intervention and preventive care. AI models can predict disease outbreaks, hospital readmissions, and patient deterioration, allowing healthcare providers to take proactive measures. For example, Health Catalyst uses predictive analytics to improve patient outcomes by identifying at-risk populations and recommending timely interventions.

AI is streamlining the drug discovery and development process, significantly reducing the time and cost involved in bringing new drugs to market. Machine learning models can analyze biological data to identify potential drug candidates, predict their efficacy, and optimize clinical trial designs. This approach accelerates the discovery of new treatments for various diseases. Notable companies in this space include BenevolentAI and Insilico Medicine, which use AI to identify new therapeutic targets and develop novel drugs.

AI is also improving the efficiency of administrative tasks and workflow management in healthcare. By automating routine tasks such as scheduling, billing, and patient data management, AI helps reduce administrative burdens on healthcare providers, allowing them to focus more on patient care. AI-powered systems can streamline operations, reduce errors, and lower operational costs. Companies like Olive and UiPath are developing AI solutions that automate healthcare administrative processes, enhancing overall efficiency.

Key Statistics and Market Trends

The AI health technology market is experiencing rapid growth, driven by the increasing adoption of AI solutions across various healthcare applications. According to a report by Grand View Research, the global AI in healthcare market size was valued at USD 10.4 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 37.5% from 2022 to 2030. This growth is fueled by factors such as the rising demand for personalized medicine, advancements in AI technology, and the increasing volume of healthcare data.

In addition, a report by Accenture estimates that AI applications can potentially save the U.S. healthcare economy up to USD 150 billion annually by 2026. These savings come from reducing unnecessary hospitalizations, optimizing resource utilization, and improving clinical outcomes through early detection and intervention.

As the healthcare industry continues to embrace AI and machine learning, the opportunities for innovation and investment are vast. In the following sections, we will delve deeper into the major areas of impact and provide insights into evaluating investment opportunities in this transformative field.

Major Areas of Impact

AI Algorithms for Medical Imaging:

AI algorithms are transforming medical imaging by providing advanced tools that enhance the accuracy and efficiency of diagnostic processes. These algorithms can analyze medical images such as X-rays, MRIs, and CT scans, identifying patterns and anomalies that might be missed by human radiologists. Deep learning techniques, in particular, have shown remarkable ability to detect conditions like cancer, cardiovascular diseases, and neurological disorders with high precision.

Examples of Successful AI Diagnostic Tools:

Several AI diagnostic tools have already proven successful in clinical settings. For example, Google's DeepMind developed an AI system that can diagnose eye diseases from retinal scans with an accuracy comparable to leading experts. Similarly, Zebra Medical Vision's AI solutions can read medical imaging scans to detect a range of conditions, from liver disease to breast cancer. Aidoc's AI-powered radiology platform helps radiologists prioritize urgent cases and improve diagnostic accuracy.

Investment Opportunities in Companies Developing Diagnostic AI Tools:

Investing in companies that develop AI diagnostic tools presents a significant opportunity. The growing demand for accurate and efficient diagnostic solutions, coupled with advancements in AI technology, makes this sector highly attractive. Companies like Aidoc, Zebra Medical Vision, and Arterys are leading the way and represent promising investment opportunities. Investing in these companies can yield high returns while contributing to the improvement of diagnostic accuracy and patient outcomes.

Role of AI in Tailoring Treatments to Individual Patients:

AI plays a crucial role in personalized medicine by analyzing vast amounts of genetic, clinical, and lifestyle data to tailor treatments to individual patients. Machine learning algorithms can identify the most effective treatment plans based on a patient's unique genetic makeup and health history. This approach leads to more precise and effective therapies, reducing the trial-and-error aspect of traditional treatments.

Success Stories and Case Studies

Personalized medicine has shown success in various fields, particularly oncology. For instance, Tempus uses AI to analyze clinical and molecular data, helping oncologists develop personalized cancer treatment plans. Another example is Foundation Medicine, which uses genomic profiling to match cancer patients with targeted therapies and clinical trials, significantly improving patient outcomes.

Companies Leading in Personalized Medicine AI:

Leading companies in the personalized medicine space include Tempus, Foundation Medicine, and GNS Healthcare. These companies leverage AI to provide tailored treatment options and improve patient care. Investing in these firms offers substantial growth potential as the demand for personalized medicine continues to rise.

Predictive Analytics

AI in Predicting Disease Outbreaks and Patient Outcomes

Predictive analytics powered by AI can forecast disease outbreaks and patient outcomes by analyzing historical and real-time data. These predictive models help healthcare providers take proactive measures, such as early interventions and resource allocation, to mitigate risks and improve patient care.

Real-World Applications and Benefits

In practice, predictive analytics has been used to predict hospital readmissions, patient deterioration, and even disease outbreaks. For example, Health Catalyst uses predictive models to identify at-risk patients and recommend timely interventions, leading to better patient outcomes and reduced healthcare costs. BlueDot, another AI company, successfully predicted the outbreak of COVID-19, showcasing the potential of AI in global health surveillance.

Startups and Firms Focusing on Predictive Analytics in Healthcare

Startups like Health Catalyst, Lumiata, and BlueDot are making significant strides in predictive analytics. These companies offer innovative solutions that help healthcare providers predict and prevent adverse health events. Investing in these startups can be highly lucrative as predictive analytics becomes an integral part of healthcare systems worldwide.

Drug Discovery and Development

AI-Driven Drug Discovery Processes:

AI is revolutionizing drug discovery by analyzing biological data to identify potential drug candidates, predict their efficacy, and optimize clinical trial designs. This approach significantly reduces the time and cost associated with traditional drug discovery methods.

Reducing Time and Cost of Bringing Drugs to Market:

AI-driven drug discovery accelerates the development of new treatments by identifying promising compounds faster and more accurately. This reduction in time and cost is crucial in addressing urgent medical needs and bringing life-saving drugs to market more efficiently.

Key Players and Emerging Startups in This Space:

Key players in AI-driven drug discovery include BenevolentAI, Insilico Medicine, and Atomwise. These companies use AI to uncover new therapeutic targets and develop novel drugs. Emerging startups like Recursion Pharmaceuticals and Exscientia are also making significant contributions to this field. Investing in these companies offers substantial growth potential as AI continues to reshape the drug discovery landscape.

Administrative Tasks and Workflow Optimization

AI in Automating Administrative Tasks:

AI is improving healthcare efficiency by automating routine administrative tasks such as scheduling, billing, and patient data management. This automation reduces administrative burdens on healthcare providers, allowing them to focus more on patient care.

Improving Efficiency and Reducing Costs:

AI-driven automation enhances operational efficiency, reduces errors, and lowers operational costs. For instance, Olive AI automates repetitive administrative tasks, leading to significant cost savings for healthcare organizations. UiPath offers robotic process automation (RPA) solutions that streamline healthcare workflows and improve overall efficiency.

Investment Potential in Companies Offering AI Solutions for Healthcare Administration:

Investing in companies that provide AI solutions for healthcare administration presents significant opportunities. As healthcare organizations increasingly adopt AI to streamline operations, companies like Olive AI, UiPath, and Automation Anywhere stand to benefit. These firms represent promising investment prospects due to their innovative solutions and growing market demand.

Evaluating Investment Opportunities

Key Metrics for Assessing AI/ML HealthTech Investments

Technological Innovation and Uniqueness:

When evaluating AI/ML HealthTech investments, one of the most critical factors is the level of technological innovation and uniqueness. Investors should look for companies that offer groundbreaking solutions with a distinct competitive edge. This could be in the form of proprietary algorithms, unique data sets, or innovative applications of AI in healthcare. The ability of a technology to address unmet medical needs or significantly improve existing processes is a strong indicator of its potential success.

Market Potential and Scalability:

The market potential and scalability of an AI/ML HealthTech solution are crucial metrics to consider. Investors should assess the size of the target market, the growth rate of the sector, and the solution's ability to scale across different regions and applications. A scalable solution that can be adapted to various healthcare settings or integrated with existing systems is more likely to achieve widespread adoption and generate substantial returns.

Regulatory Landscape and Compliance:

Navigating the regulatory landscape is a significant challenge in the healthcare industry. Investors should evaluate the company's understanding of and compliance with relevant regulations, such as the FDA's guidelines for AI/ML-based medical devices or the GDPR for data privacy. A company's ability to achieve regulatory approval and maintain compliance is essential for long-term success and market entry.

Financial Health and Funding History:

The financial health of a company is another key metric for assessing investment opportunities. Investors should review the company's financial statements, funding history, and revenue projections. Companies with a strong financial foundation and a history of securing funding from reputable sources are generally more stable and capable of sustaining growth. Additionally, the ability to attract high-profile investors or partnerships can be a positive indicator of a company's potential.

Leadership and Team Expertise:

The expertise and experience of a company's leadership and team are vital to its success. Investors should assess the backgrounds of key team members, including their experience in AI, healthcare, and business development. A strong leadership team with a proven track record can drive innovation, navigate challenges, and execute the company's vision effectively.

Risks and Challenges

Ethical Considerations and Data Privacy Issues:

Ethical considerations and data privacy issues are significant challenges in the AI/ML HealthTech sector. Investors should be aware of the ethical implications of AI applications, such as potential biases in algorithms and the impact on patient care. Additionally, ensuring data privacy and security is critical, as healthcare data is highly sensitive. Companies that prioritize ethical practices and robust data protection measures are better positioned to gain trust and succeed in the market.

Regulatory Hurdles and Approval Processes:

Regulatory hurdles and approval processes can be major obstacles for AI/ML HealthTech companies. Obtaining regulatory approval can be time-consuming and costly, and any delays or failures in this process can significantly impact a company's ability to bring its products to market. Investors should consider the regulatory landscape and the company's strategy for navigating these challenges.

Technological Limitations and Reliability:

The technological limitations and reliability of AI/ML solutions are also important considerations. While AI offers immense potential, it is not without its limitations. Issues such as algorithmic biases, data quality, and system reliability can affect the performance and acceptance of AI solutions. Investors should evaluate the robustness of the technology, the quality of the data used for training models, and the company's approach to addressing these limitations.

Case Studies of Successful Investments

Detailed Examples of Successful AI/ML HealthTech Investments

Example 1: Tempus

Tempus, a leading company in precision medicine, leverages AI and ML to analyze clinical and molecular data, helping oncologists develop personalized cancer treatment plans. Since its founding in 2015, Tempus has raised over $1 billion in funding, with a valuation exceeding $8 billion. The company's success can be attributed to its robust data infrastructure, advanced analytics capabilities, and strong partnerships with healthcare institutions.

Example 2: Zebra Medical Vision

Zebra Medical Vision has developed AI-powered tools for medical imaging, capable of detecting a wide range of conditions from imaging scans. The company has secured significant investments, including $30 million in a Series C funding round led by aMoon and Aurum Ventures. Zebra's success stems from its innovative technology, regulatory approvals, and strategic partnerships with healthcare providers and imaging equipment manufacturers.

Example 3: Health Catalyst

Health Catalyst focuses on using AI for predictive analytics and data warehousing in healthcare. The company went public in 2019, raising $182 million in its initial public offering (IPO). Health Catalyst's success is due to its comprehensive data platform, which integrates various healthcare data sources to provide actionable insights. The company's commitment to improving patient outcomes and reducing healthcare costs has resonated with investors and healthcare organizations alike.

Example 4: Notable Labs

Notable Labs has been actively involved in AI and machine learning investments within the HealthTech sector, focusing on innovative solutions that enhance precision medicine, diagnostics, and patient care. By leveraging cutting-edge AI technologies, Notable Labs aims to streamline clinical workflows, improve disease prediction and prevention, and personalize treatment plans. Their investment strategy targets startups and established companies that are pioneering advancements in medical AI, fostering a collaborative ecosystem that accelerates the development and deployment of transformative healthcare solutions. This proactive approach positions Notable Labs at the forefront of the HealthTech revolution, driving significant improvements in patient outcomes and healthcare efficiency.

Analysis of What Made These Investments Successful

Tempus

Robust Data Infrastructure: Tempus built a vast and well-structured database of clinical and molecular data, which is crucial for training effective AI models.
Advanced Analytics Capabilities: The company's ability to analyze complex datasets and generate actionable insights has been a key differentiator.
Strong Partnerships: Collaborations with leading healthcare institutions and research organizations have enhanced Tempus's credibility and reach.
Clear Value Proposition: Tempus's focus on personalized cancer treatment addresses a significant unmet need, making its solutions highly valuable.

Zebra Medical Vision

Innovative Technology: Zebra's AI algorithms have demonstrated high accuracy in detecting various medical conditions, setting a new standard in medical imaging.
Regulatory Approvals: Achieving regulatory approvals for its AI tools has been critical for market entry and adoption.
Strategic Partnerships: Collaborations with imaging equipment manufacturers and healthcare providers have facilitated the integration of Zebra's technology into clinical workflows.
Scalability: The company's solutions are designed to be scalable across different healthcare settings, increasing their market potential.

Health Catalyst

Comprehensive Data Platform: Health Catalyst's platform integrates diverse healthcare data sources, providing a holistic view of patient care.
Focus on Outcomes: The company's emphasis on improving patient outcomes and reducing costs has aligned with the priorities of healthcare providers.
Successful IPO: Going public provided Health Catalyst with the capital needed to expand its operations and invest in further technological advancements.
Strong Market Demand: The growing need for data-driven decision-making in healthcare has driven demand for Health Catalyst's solutions.

Notable Labs:

Innovative AI Integration: Notable Labs leverages AI and machine learning in their Predictive Precision Medicine Platform (PPMP) to predict patient responses to treatments, significantly enhancing precision medicine approaches.
Clinical Validation: Multiple studies have demonstrated PPMP's high predictive precision, including a 100% accuracy rate in predicting clinical responders for certain AML treatments.
Strategic Mergers and Funding: Recent merger with VBL Therapeutics and securing $10.3 million in new capital have bolstered its capacity to advance clinical development and expand its pipeline.
Focus on Patient Outcomes: The platform's ability to bio-simulate cancer treatments and predict responses reduces the risk and accelerates drug development, promising better patient outcomes and cost efficiency.

Lessons Learned and Best Practices for Investors

Focus on Data Quality and Integration:

Investing in companies with high-quality, well-integrated data is crucial. Robust data infrastructure is the backbone of effective AI/ML solutions in healthcare. Companies that can aggregate and analyze diverse datasets are better positioned to deliver valuable insights and outcomes.

Evaluate Technological Innovation and Regulatory Strategy:

Technological innovation and the ability to navigate regulatory landscapes are key determinants of success. Investors should assess the uniqueness of the technology and the company's strategy for achieving regulatory approvals. Regulatory compliance not only ensures market entry but also builds trust with healthcare providers and patients.

Assess Market Potential and Scalability:

The market potential and scalability of AI/ML HealthTech solutions are critical factors to consider. Solutions that can be adapted to various healthcare settings and integrated with existing systems are more likely to achieve widespread adoption and generate substantial returns.

Prioritize Ethical Practices and Data Privacy:

Ethical considerations and data privacy are paramount in healthcare. Investors should prioritize companies that adhere to ethical AI practices and implement robust data protection measures. Companies that prioritize patient privacy and data security are more likely to gain trust and succeed in the long term.

Consider Leadership and Team Expertise:

The expertise and experience of a company's leadership and team are vital to its success. A strong leadership team with a proven track record in AI, healthcare, and business development can drive innovation and execute the company's vision effectively.

Recap of the transformative potential of AI and machine learning in health technology

AI and machine learning are revolutionizing health technology, driving advancements across diagnostics, personalized medicine, predictive analytics, drug discovery, and administrative workflows. These technologies enhance diagnostic accuracy, tailor treatments to individual patients, predict health outcomes, streamline drug development, and optimize healthcare operations. The impact of AI/ML in HealthTech is profound, improving patient outcomes, reducing costs, and increasing efficiency in healthcare delivery.

Strategic investments in AI and machine learning within the health technology sector are crucial for continued innovation and growth. By investing in companies that lead in technological innovation, have a clear understanding of regulatory landscapes, and prioritize ethical practices and data privacy, investors can drive significant advancements in healthcare. These investments not only offer substantial financial returns but also contribute to the betterment of global health.

The opportunities for investment in AI and ML HealthTech are vast and varied. From diagnostic tools that enhance disease detection to predictive analytics that forecast health trends, the potential for innovation is limitless. Investors are encouraged to explore these opportunities, as the integration of AI and ML in healthcare is still in its early stages, with immense potential for growth and impact.

We invite our readers to share their thoughts, experiences, and insights on AI and machine learning in health technology. Engaging with the content through comments and discussions helps foster a community of informed and passionate individuals dedicated to advancing HealthTech.

< Older Post Newer Post >

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024

Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.

A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024

Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.

A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024

Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.

A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024

Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.

A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024

Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.

A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024

Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.

Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024

Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.

A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024

Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.

A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024

Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.

A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024

Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial. Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.